Comment into chart
First entry point 280 (as it is now) > if this is a "head-shoulders"
TP 1 > 297 | TP2 > 302 | TP3 > 311
(SL 276)
Second entry point 268 (if bad earnings) > 0.5 retracement + patern D point
TP 1 > 276 | TP2 > 285 | TP3 > 297
(SL 264)
Ref >
> barrons.com/articles/expect-a-strong-quarter-from-biogen-instinet-1500044368?mod=yahoobarrons&ru=yahoo&yptr=yahoo
> barrons.com/articles/three-biotechs-that-look-best-positioned-ahead-of-q2-earnings-1499710784?mod=yahoobarrons&ru=yahoo&yptr=yahoo
> fool.com/investing/2017/07/13/how-biogen-inc-makes-most-of-its-money.aspx
> swingtradebot.com/equities/BIIB/recent-events
> chartmill.com/analyze.php
First entry point 280 (as it is now) > if this is a "head-shoulders"
TP 1 > 297 | TP2 > 302 | TP3 > 311
(SL 276)
Second entry point 268 (if bad earnings) > 0.5 retracement + patern D point
TP 1 > 276 | TP2 > 285 | TP3 > 297
(SL 264)
Ref >
> barrons.com/articles/expect-a-strong-quarter-from-biogen-instinet-1500044368?mod=yahoobarrons&ru=yahoo&yptr=yahoo
> barrons.com/articles/three-biotechs-that-look-best-positioned-ahead-of-q2-earnings-1499710784?mod=yahoobarrons&ru=yahoo&yptr=yahoo
> fool.com/investing/2017/07/13/how-biogen-inc-makes-most-of-its-money.aspx
> swingtradebot.com/equities/BIIB/recent-events
> chartmill.com/analyze.php
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.